RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 30.56% | 33.64% | 46.98% | 33.13% | 24.59% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -75.67% | -91.06% | -73.68% | -29.29% | 43.49% |
| Total Other Non-Cash Items | 255.54% | 219.94% | 266.29% | 658.99% | -158.84% |
| Change in Net Operating Assets | -27.90% | -21.02% | -30.84% | -11.19% | -7.56% |
| Cash from Operations | 20.28% | 38.63% | 78.35% | 84.96% | 67.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -62.51% | -39.53% | -64.09% | -71.67% | -65.22% |
| Total Debt Repaid | 74.24% | -75.00% | -2,004.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.00% | -- | -- | 200.00% |
| Cash from Financing | -18.15% | -30.21% | -78.19% | -85.09% | -67.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,360.00% | 122.81% | 98.04% | -360.00% | -266.67% |